Kallikrein 9 anticorps (C-Term)

N° du produit ABIN3031531

Détail du produit anti-Kallikrein 9 anticorps

Antigène: Kallikrein 9 (KLK9)

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Kallikrein 9 est non-conjugé

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogène: An amino acid sequence from the C-terminus of human Kallikrein 9 (SVCHYLDWIQEIMEN) was used as the immunogen for this Kallikrein 9 antibody.

Isotype: IgG

Information d'application

Indications d'application: The stated application concentrations are suggested starting amounts. Titration of the Kallikrein 9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Stockage

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Stock: -20 °C

Stockage commentaire: After reconstitution, the Kallikrein 9 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Détails sur Kallikrein 9

Antigène: Kallikrein 9 (KLK9)

Autre désignation: Kallikrein 9 (KLK9 Produits)

Synonymes: anticorps KLK-L3, anticorps KLKL3, anticorps 1200016C12Rik, anticorps AI324041, anticorps Klk9, anticorps Klks3, anticorps rGK-9, anticorps rK9, anticorps kallikrein related peptidase 9, anticorps kallikrein related-peptidase 9, anticorps kallikrein 1-related peptidase C9, anticorps KLK9, anticorps Klk9, anticorps Klk1c9

Sujet: Kallikrein-related peptidase 9, also known as KLK9 or KLK-L3, belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues. The KLK9 gene contains 5 coding exons and is mapped to 19q13.41. The gene is regulated by steroid hormones in a human breast cancer cell line. Yousef et al.(2001) performed a quantitative analysis of KLK9 expression in ovarian cancer. The results indicated that KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. KLK9 is a potential independent favorable prognostic marker for early-stage, low-grade, optimally debulked ovarian cancer patients.

UniProt: Q9UKQ9

Pathways: Système du Complément